A rather unusual company to be receiving SBIR support, Cadre Bioscience are a team of business professionals focused on development of a portfolio of early-stage therapeutic assets. Utilizing an experienced management team, accelerator lab facilities and an extensive network of consultants and collaborators the firm offers what is described as an alternative for innovators wishing to see their technology(ies) that they have developed for the benefit of patients without the need for them to tackle the niceties of founding their own company and raising capital. The Cadreâs experience, infrastructure and network creates greater efficiencies, shortens timelines, and increases chances of success. In their description of the firm, management note that the traditional route of pursuing a commercial path for a therapeutic technology via formation of a start-up company comes with numerous challenges: raising of capital, attracting suitably experienced management and creating a development plan. Often the availability of suitable business and development experience is limited, so that building a company around a single technology during the earliest stages of development is inherently inefficient. By providing a source of this experience and expertise for multiple technologies under the same umbrella, Cadre provides an attractive means for innovators to launch their technology down a path towards commercialization and providing patient benefit. In sum, Cadre Bioscience offers an alternative of their advancing the firm's fledgling therapeutic technology. raising the required venture capital investment needed to rsablish the stand-alone company - that can then fly the Cadre nest with their own dedicated funding, leadership and scientific team
